Abstract: Asporogenous mutant B. subtilis RUB 331 (ATCC 31578) and a process for using such mutant are disclosed. The asporogenous mutant desirably reverts to sporeformers with a frequency not greater than 10.sup.-7 reversions per bacterium per generation and meets the requirements of the NIH "Guidelines for Research Involving Recombinant DNA Molecules" for a B. subtilis host component of a Host-Vector 1 system.

Abstract: A method for the purification of lipoprotein cholesterol. The method involves the steps of adsorbing lipoprotein material on a silica adsorbant, eluting the adsorbed lipoprotein with water at a pH of about 10 to 11.5, adjusting the salt concentration to about less than 0.05M, heating the lipoprotein to about 50.degree. to 100.degree. C. for a period of about 5 minutes to 24 hours, adding an alkaline carbonate and alkaline earth salt to form a precipitate and removing the precipitate, adjusting the pH from about 6.5 to 9.0 and recovering purified lipoprotein cholesterol. Also a method for using the cholesterol as a cholesterol reference material.

Abstract: Analogues of PGE.sub.1 having the structural formula, ##STR1## in which J is R-hydroxymethylene or S-hydroxymethylene; R.sub.1 is hydrogen; R.sub.2 is hydrogen or together with R.sub.4 is a methylene chain of 2 to 3 carbon atoms such that a cycloalkyl of 5 to 6 carbon atoms inclusive is formed; R.sub.3 is hydrogen or methyl, or together with R.sub.4 is a methylene or a lower alkylated methylene chain of 2 to 5 carbon atoms such that a cycloalkyl or a lower alkylated cycloalkyl of 4 to 7 carbon atoms inclusive is formed, or together with R.sub.4 is bicycloalkyl or bicycloalkenyl moiety having the formula: ##STR2## such that a bicycloalkyl or bicycloalkenyl compound is formed, wherein m and n are integers having a value from 0 to 3, p is an integer having a value from 0 to 4 and q is an integer having a value of from 1 to 4 and wherein the double bond of such bicycloalkenyl is in the m, n, p, or q bridge; R.sub.4 is hydrogen or methyl or together with R.sub.2 or R.sub.

Abstract: A method and composition for the hydrolysis and assay of triglycerides are disclosed. The method includes the steps of adding lipase and cholesterol esterase to a triglyceride in combination with a glycerol assay system and determining the amount of triglycerides present based on the amount of glycerol produced. The composition includes a mixture of lipase, cholesterol esterase and a glycerol assay system.

Abstract: Compounds which are 3-methylene flavanones and 3-methylene chromanones having activity against microorganisms are disclosed. The compounds are represented by the general structural formula: ##STR1## wherein: R.sup.1 is a member selected from the group consisting of hydrogen, Br, CH.sub.3 and OCH.sub.3 ; R.sup.2 is selected from the group consisting of hydrogen and ##STR2## wherein R.sup.4 is a member selected from the group consisting of hydrogen, Br, Cl, CH.sub.3, OCH.sub.3, NO.sub.2, N(CH.sub.3).sub.3 and CN; R.sup.5 is selected from the group consisting of hydrogen and Cl, with the proviso that when R.sup.5 is Cl, R.sup.4 is hydrogen or Cl; and R.sup.3 is selected from the group consisting of hydrogen, phenyl, 2-thienyl, 4-pyridyl and naphthyl, with the proviso that when R.sup.3 is naphthyl, R.sup.1 and R.sup.2 are hydrogen.

Abstract: 1-(4-Cyano-phenoxy)-2-hydroxy-3-[2-(5-1H-tetrazolyl)-chromon-5-yloxy]-propa ne and its pharmacologically acceptable salts, are useful in the treatment of allergies, allergic asthma and inflammation.

Abstract: Certain substituted cycloalkenochromones and pharmacologically acceptable salts thereof are disclosed as being useful in the treatment of allergies. The compounds have the structure: ##STR1## X is --O--, --S--, or --SO.sub.2. Y is from 1 to 4. R.sub.1 is H or alkyl, and R.sub.2 is H, alkyl, aryl, carboxyl, alkoxy, aralkoxy, or alkoxycarbonyl. When R.sub.1 is alkyl, R.sub.2 is hydrogen, alkyl or aryl. At least one of R.sub.2 and R.sub.3 is alkoxycarbonyl, carboxyl or tetrazolyl. R.sub.3 is carboxyl, alkylthio, alkylsulfonyl, alkylsulfinyl, alkoxycarbonyl, or tetrazolyl.

Abstract: The standardization of a labelled constituent, such as anti-IgE, for use in a specific binding assay method is disclosed. The method involves standardizing a labelled ligand (eg., radiolabelled IgE) against a ligand reference substance (eg., WHO standard IgE) to determine the weight of IgE protein represented by the labelled ligand, expressed in terms of the reference substance (eg., WHO units). Anti-light chain antibodies are attached to a solid phase and contacted with varying concentrations of the labelled ligand to bind the ligand to the anti-light chain antibodies. The ligand is then contacted with the labelled constituent and the amount of labelled constituent, in relation to the amount of ligand protein present, expressed in terms of the reference substance, is determined. The labelled constituent is thus standardized, since the actual weight of a ligand can be determined from the amount of labelled constituent bound thereto.

Abstract: Analogues of prostaglandins A, E and F in which a phenyl moiety is attached to the C.sub.14 carbon atom are disclosed. Also disclosed are methods of preparing the analogues and starting materials. The compounds have the structural formula: ##STR1## in which J is methylene, R or S-hydroxymethylene or methine; L is methylene or methine and can be methine only when J is methine; M is carbonyl, R or S-hydroxymethylene; Q is ethylene, Z-vinylene or inter-phenylene; T is an alkoxy-carbonyl having from 2 to 3 carbon atoms inclusive, or carboxyl; and B is a loweralkyl of from 1 to 5 carbon atoms.The prostaglandin analogues of the present invention exhibit a separation of pharmacological activity. The analogues can be used for platelet aggregation (and Methyl 14-Phenyl-11.alpha.,15S-dihydroxy-9-oxoprost-13E-en-1-oate can be used for antagonism for smooth muscle stimulation) without the accompanying undesirable side effects of natural prostaglandins, e.g., flush, headache, abdominal cramps and nausea.

Abstract: Analogues of PGE.sub.1 having the structural formula, ##STR1## in which J is R-hydroxymethylene or S-hydroxymethylene; R.sub.1 is hydrogen; R.sub.2 is hydrogen or together with R.sub.4 is a methylene chain of 2 to 3 carbon atoms such that a cycloalkyl of 5 to 6 carbon atoms inclusive is formed; R.sub.3 is hydrogen or methyl, or together with R.sub.4 is a methylene or a lower alkylated methylene chain of 2 to 5 carbon atoms such that a cycloalkyl or a lower alkylated cycloalkyl of 4 to 7 carbon atoms inclusive is formed, or together with R.sub.4 is bicycloalkyl or bicycloalkenyl moiety having the formula: ##STR2## SUCH THAT A BICYCLOALKYL OR BICYCLOALKENYL COMPOUND IS FORMED, WHEREIN M AND N ARE INTEGERS HAVING A VALUE FROM 0 TO 3, P IS AN INTEGER HAVING A VALUE FROM 0 TO 4 AND Q IS AN INTEGER HAVING A VALUE OF FROM 1 TO 4 AND WHEREIN THE DOUBLE BOND OF SUCH BICYCLOALKENYL IS IN THE M, N, P, OR Q BRIDGE; R.sub.4 is hydrogen or methyl or together with R.sub.2 or R.sub.

Abstract: A high molecular weight extract of mammalian blood plasma and serum proteins of the group Cohn fraction IV, Cohn subfraction IV.sub.1, IV.sub.4 and haptoglobin, have been found to contain activity which inhibits endogenous prostaglandin synthetase. This extract is therefore of utility in treating or alleviating pathological conditions associated with excessive or unbalanced snythesis of endogenous prostaglandins, for example, in reducing bronchoconstriction or treating arthritis. For this purpose, the extract may be administered by injection, by inhalation, or topically.

Abstract: 19-Hydroxy carbinol analogues of PGE.sub.1 having the structure ##STR1## are disclosed as bronchodilators. Methods of preparing the analogues are also disclosed.

Abstract: A method for the preparation of purified prostaglandin synthetase from bovine seminal vesicles is disclosed. The method includes the steps of homogenizing bovine seminal vesicles with a liquid medium to form an homogenate and centrifuging the homogenate at a speed such that the centrifugal force does not exceed 1,000g. The supernatant obtained, containing prostaglandin synthetase, is separated from the solids.

Abstract: A method for producing molded reinforced articles by contact molding is disclosed. The improved method involves working a resin-glass fiber composition into a reinforcing mat by rolling across the mat, along a longitudinally-extending axis spaced from the mat, laterally incremental forces to the mat. The forces are applied at different elevations laterally of the mat, depending on the configuration. As the forces are applied to the reinforcing mat, the height of resin flow laterally incrementally of the mat is also controlled.

Abstract: A reinforced polyester door is disclosed. The door has an interior supporting frame, rigid front and back surface skins, an insulating foam layer between the front and back surface, and a reinforcing member adjacent the latch side of the door. Magnetizable particles are preferably placed within the front surface skin along the periphery of the door.

Abstract: A method for producing heterocyclic acid anhydrides and pyrimidinediones from the corresponding acids, dicarboxamides, 2,3-and 3,4-pyridinedicarboxamides, and N-monosubstituted 2,3-and 3,4-pyridinedicarboxamides, in which the aforesaid compounds are reacted with lead tetra-acetate in the presence of a suitable anhydrous inert solvent.

Abstract: A method for producing heterocyclic acid anhydrides and pyrimidinediones from the corresponding acids, dicarboxamides, 2,3-and 3,4-pyridinedicarboxamides, and N-monosubstituted 2,3-and 3,4-pyridinedicarboxamides, in which the aforesaid compounds are reacted with lead tetra-acetate in the presence of a suitable anhydrous inert solvent.

Abstract: An improved ceramic article useful after firing as an electrical suppressor element especially suitable for use in spark plugs is disclosed. The suppressor element is an aluminum-manganese oxide composition modified with a strontium compound which optionally may contain a nickel compound. The numerical value of the atom ratio of the article ##EQU1## IS CONTROLLED FROM 0.1 TO 1.5. The strontium/aluminum atom ratio has a value of from 0.5:1 to 0.95:1. The manganese constitutes from 50 percent to 100 percent based upon the total atoms of manganese and nickel present. The temperature coefficient of resistance of the suppressor, defined by ##EQU2## is between about -2.8%/.degree.C and -1.3%/.degree.C.